246 related articles for article (PubMed ID: 21572154)
1. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
Keystone EC
J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
3. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP; Einarson TR; Keystone EC
Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF therapy: safety aspects of taking the risk.
Rosenblum H; Amital H
Autoimmun Rev; 2011 Jul; 10(9):563-8. PubMed ID: 21570495
[TBL] [Abstract][Full Text] [Related]
5. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Thompson AE; Rieder SW; Pope JE
Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
[TBL] [Abstract][Full Text] [Related]
7. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A; Greenberg JD
Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
[TBL] [Abstract][Full Text] [Related]
8. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
10. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
11. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
13. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
14. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.
Lassoued S; Zabraniecki L; Marin F; Billey T
Semin Arthritis Rheum; 2007 Feb; 36(4):262-3. PubMed ID: 17067660
[TBL] [Abstract][Full Text] [Related]
15. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
16. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
17. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].
Xie X; Chen J; Peng Y; Gao J; Tian J; Ling G; Du J; Mao N; Wu P; Li F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082
[TBL] [Abstract][Full Text] [Related]
18. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
19. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
Ang HT; Helfgott S
J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
